Procter & Gamble Health Approves Financial Results and Recommends Dividend for FY 2026
Procter & Gamble Health Limited (P&G Health) announced the approval of its audited financial results for the Financial Year ending March 31, 2026, following a meeting of the Board of Directors held on May 26, 2026. During the board meeting, the company also recommended a final dividend payment.The Board of Directors recommended a dividend of Rs. 45 per Equity Share (with a nominal value of Rs. 10 each) for the Financial Year ending March 31, 2026. This dividend is subject to approval by the Members at the ensuing Annual General Meeting and is scheduled for payment on or before September 25, 2026. The company also noted that the total dividend for the financial year, including an interim dividend and a one-time special dividend of Rs. 160 per equity share, totals Rs. 205 per equity share.
Financial Performance Summary
The company released audited financial statements for the quarter and the full financial year ended March 31, 2026.The following table summarizes key financial metrics in lakhs:
| Particulars | Three months ended 31st March 2026 (Audited) | Three months ended 31st March 2025 (Audited) | Current Year (12 Months) ended 31st March 2026 (Audited) | Previous Year (Nine Months) ended 31st March 2025 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 37,045 | 31,099 | 140,797 | 93,417 |
| Total Income (1+2) | 37,445 | 31,410 | 142,531 | 94,452 |
| Total expenses | 24,124 | 23,557 | 97,545 | 63,290 |
| Profit before tax | 13,321 | 7,853 | 44,986 | 31,162 |
| Total tax expenses | 3,861 | 1,735 | 12,295 | 7,721 |
| Net Profit for the period / year | 9,460 | 6,118 | 32,691 | 23,441 |
| Total Comprehensive Income | 9,167 | 6,038 | 32,663 | 23,179 |
| Earnings per equity share (Basic and Diluted) | 56.99 | 36.86 | 196.94 | 141.22 |
Balance Sheet Highlights
The audited statement of assets and liabilities as of March 31, 2026, showed the company's total equity and liabilities stood at 84,135 lakhs, compared to 79,420 lakhs in the previous year.The table below details the key components of the Balance Sheet:
| Particulars | As at March 31, 2026 (Audited) (in Lakhs) | As at March 31, 2025 (Audited) (in Lakhs) |
|---|---|---|
| Non-current assets (Total) | 28,509 | 26,781 |
| Total current assets | 55,626 | 52,639 |
| Total Equity and Liabilities | 84,135 | 79,420 |
| Total equity | 52,455 | 53,696 |
| Total non-current liabilities | 6,187 | 4,193 |
| Total current liabilities | 25,493 | 21,531 |
Cash Flow Statement Overview
The statement of cash flows for the financial year ended March 31, 2026, showed significant net cash flows generated from operating activities.| Particulars | Financial Year ended March 31, 2026 (Audited) (in lakhs) | Financial Year (nine months) ended March 31, 2025 (Audited) (in lakhs) |
|---|---|---|
| Cash generated from operations | 44,164 | 25,001 |
| Net cash flows generated from operating activities (A) | 33,779 | 16,869 |
| Net cash flows generated from investing activities (B) | 126 | 959 |
| Net cash flows (used in) financing activities (C) | (34,392) | (23,474) |
| Net (decrease) in cash and cash equivalents (A+B+C) | (487) | (5,646) |
| Cash and cash equivalents at the end of the year | 17,740 | 18,227 |
The company's reported cash and cash equivalents at the end of the year amounted to 17,740 lakhs, compared to 18,227 lakhs in the previous period.
The statutory auditors, Haribhakti & Co. LLP, issued an opinion on the annual financial results, confirming that the statement gives a true and fair view of the net profit and other comprehensive income for the year ended March 31, 2026.
PGHL Stock Price Movement
Shares of Procter & Gamble Health Limited today slipped by 1.12% to settle at ₹5652.5. The stock traded within a range of ₹5599 to ₹5760, completing its session on a total volume of 15,617 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: